The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells

Donatella Malanga, Carmela De Marco, Ilaria Guerriero, Fabiana Colelli, Nicola Rinaldo, Marianna Scrima, Teresa Mirante, Claudia De Vitis, Pietro Zoppoli, Michele Ceccarelli, Miriam Riccardi, Maria Ravo, Alessandro Weisz, Antonella Federico, Renato Franco, Gaetano Rocco, Rita Mancini, Antonia Rizzuto, Elio Gulletta, Gennaro Ciliberto & 1 others Giuseppe Viglietto

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Here we report that the PI3K/Akt1/IL-6/STAT3 signalling pathway regulates generation and stem cell-like properties of Non-Small Cell Lung Cancer (NSCLC) tumor initiating cells (TICs). Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and tumorigenic potential of human immortalized bronchial cells (BEAS-2B) whereas Akt inhibition suppresses these activities in established (NCI-H460) and primary NSCLC cells. Matched microarray analysis of Akt1-interfered cells and LCSs identified IL-6 as a critical target of Akt signalling in NSCLC TICs. Accordingly, suppression of Akt in NSCLC cells decreases IL-6 levels, phosphorylation of IkK and IkB, NF-kB transcriptional activity, phosphorylation and transcriptional activity of STAT3 whereas active Akt1 up-regulates them. Exposure of LCSs isolated from NSCLC cells to blocking anti-IL-6 mAbs, shRNA to IL-6 receptor or to STAT3 markedly reduces the capability to generate LCSs, to self-renew and to form tumors, whereas administration of IL-6 to Akt-interfered cells restores the capability to generate LCSs. Finally, immunohistochemical studies in NSCLC patients demonstrated a positive correlative trend between activated Akt, IL-6 expression and STAT3 phosphorylation (n = 94; p <0.05). In conclusion, our data indicate that aberrant Akt signalling contributes to maintaining stemness in lung cancer TICs through a NF-kB/IL-6/ STAT3 pathway and provide novel potential therapeutic targets for eliminating these malignant cells in NSCLC.

Original languageEnglish
Pages (from-to)42667-42686
Number of pages20
JournalOncotarget
Volume6
Issue number40
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Non-Small Cell Lung Carcinoma
Interleukin-6
Lung
Growth
NF-kappa B
Phosphorylation
Lung Neoplasms
Interleukin-6 Receptors
Microarray Analysis
Phosphatidylinositol 3-Kinases
Small Interfering RNA
Up-Regulation
Stem Cells
Neoplasms

Keywords

  • Akt1
  • IL-6
  • NSCLC
  • STAT3
  • Tumor initiating cells

ASJC Scopus subject areas

  • Oncology

Cite this

Malanga, D., De Marco, C., Guerriero, I., Colelli, F., Rinaldo, N., Scrima, M., ... Viglietto, G. (2015). The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. Oncotarget, 6(40), 42667-42686. https://doi.org/10.18632/oncotarget.5626

The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. / Malanga, Donatella; De Marco, Carmela; Guerriero, Ilaria; Colelli, Fabiana; Rinaldo, Nicola; Scrima, Marianna; Mirante, Teresa; De Vitis, Claudia; Zoppoli, Pietro; Ceccarelli, Michele; Riccardi, Miriam; Ravo, Maria; Weisz, Alessandro; Federico, Antonella; Franco, Renato; Rocco, Gaetano; Mancini, Rita; Rizzuto, Antonia; Gulletta, Elio; Ciliberto, Gennaro; Viglietto, Giuseppe.

In: Oncotarget, Vol. 6, No. 40, 2015, p. 42667-42686.

Research output: Contribution to journalArticle

Malanga, D, De Marco, C, Guerriero, I, Colelli, F, Rinaldo, N, Scrima, M, Mirante, T, De Vitis, C, Zoppoli, P, Ceccarelli, M, Riccardi, M, Ravo, M, Weisz, A, Federico, A, Franco, R, Rocco, G, Mancini, R, Rizzuto, A, Gulletta, E, Ciliberto, G & Viglietto, G 2015, 'The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells', Oncotarget, vol. 6, no. 40, pp. 42667-42686. https://doi.org/10.18632/oncotarget.5626
Malanga D, De Marco C, Guerriero I, Colelli F, Rinaldo N, Scrima M et al. The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. Oncotarget. 2015;6(40):42667-42686. https://doi.org/10.18632/oncotarget.5626
Malanga, Donatella ; De Marco, Carmela ; Guerriero, Ilaria ; Colelli, Fabiana ; Rinaldo, Nicola ; Scrima, Marianna ; Mirante, Teresa ; De Vitis, Claudia ; Zoppoli, Pietro ; Ceccarelli, Michele ; Riccardi, Miriam ; Ravo, Maria ; Weisz, Alessandro ; Federico, Antonella ; Franco, Renato ; Rocco, Gaetano ; Mancini, Rita ; Rizzuto, Antonia ; Gulletta, Elio ; Ciliberto, Gennaro ; Viglietto, Giuseppe. / The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. In: Oncotarget. 2015 ; Vol. 6, No. 40. pp. 42667-42686.
@article{2497f0ea9ab947ac94a8818282677160,
title = "The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells",
abstract = "Here we report that the PI3K/Akt1/IL-6/STAT3 signalling pathway regulates generation and stem cell-like properties of Non-Small Cell Lung Cancer (NSCLC) tumor initiating cells (TICs). Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and tumorigenic potential of human immortalized bronchial cells (BEAS-2B) whereas Akt inhibition suppresses these activities in established (NCI-H460) and primary NSCLC cells. Matched microarray analysis of Akt1-interfered cells and LCSs identified IL-6 as a critical target of Akt signalling in NSCLC TICs. Accordingly, suppression of Akt in NSCLC cells decreases IL-6 levels, phosphorylation of IkK and IkB, NF-kB transcriptional activity, phosphorylation and transcriptional activity of STAT3 whereas active Akt1 up-regulates them. Exposure of LCSs isolated from NSCLC cells to blocking anti-IL-6 mAbs, shRNA to IL-6 receptor or to STAT3 markedly reduces the capability to generate LCSs, to self-renew and to form tumors, whereas administration of IL-6 to Akt-interfered cells restores the capability to generate LCSs. Finally, immunohistochemical studies in NSCLC patients demonstrated a positive correlative trend between activated Akt, IL-6 expression and STAT3 phosphorylation (n = 94; p <0.05). In conclusion, our data indicate that aberrant Akt signalling contributes to maintaining stemness in lung cancer TICs through a NF-kB/IL-6/ STAT3 pathway and provide novel potential therapeutic targets for eliminating these malignant cells in NSCLC.",
keywords = "Akt1, IL-6, NSCLC, STAT3, Tumor initiating cells",
author = "Donatella Malanga and {De Marco}, Carmela and Ilaria Guerriero and Fabiana Colelli and Nicola Rinaldo and Marianna Scrima and Teresa Mirante and {De Vitis}, Claudia and Pietro Zoppoli and Michele Ceccarelli and Miriam Riccardi and Maria Ravo and Alessandro Weisz and Antonella Federico and Renato Franco and Gaetano Rocco and Rita Mancini and Antonia Rizzuto and Elio Gulletta and Gennaro Ciliberto and Giuseppe Viglietto",
year = "2015",
doi = "10.18632/oncotarget.5626",
language = "English",
volume = "6",
pages = "42667--42686",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

TY - JOUR

T1 - The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells

AU - Malanga, Donatella

AU - De Marco, Carmela

AU - Guerriero, Ilaria

AU - Colelli, Fabiana

AU - Rinaldo, Nicola

AU - Scrima, Marianna

AU - Mirante, Teresa

AU - De Vitis, Claudia

AU - Zoppoli, Pietro

AU - Ceccarelli, Michele

AU - Riccardi, Miriam

AU - Ravo, Maria

AU - Weisz, Alessandro

AU - Federico, Antonella

AU - Franco, Renato

AU - Rocco, Gaetano

AU - Mancini, Rita

AU - Rizzuto, Antonia

AU - Gulletta, Elio

AU - Ciliberto, Gennaro

AU - Viglietto, Giuseppe

PY - 2015

Y1 - 2015

N2 - Here we report that the PI3K/Akt1/IL-6/STAT3 signalling pathway regulates generation and stem cell-like properties of Non-Small Cell Lung Cancer (NSCLC) tumor initiating cells (TICs). Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and tumorigenic potential of human immortalized bronchial cells (BEAS-2B) whereas Akt inhibition suppresses these activities in established (NCI-H460) and primary NSCLC cells. Matched microarray analysis of Akt1-interfered cells and LCSs identified IL-6 as a critical target of Akt signalling in NSCLC TICs. Accordingly, suppression of Akt in NSCLC cells decreases IL-6 levels, phosphorylation of IkK and IkB, NF-kB transcriptional activity, phosphorylation and transcriptional activity of STAT3 whereas active Akt1 up-regulates them. Exposure of LCSs isolated from NSCLC cells to blocking anti-IL-6 mAbs, shRNA to IL-6 receptor or to STAT3 markedly reduces the capability to generate LCSs, to self-renew and to form tumors, whereas administration of IL-6 to Akt-interfered cells restores the capability to generate LCSs. Finally, immunohistochemical studies in NSCLC patients demonstrated a positive correlative trend between activated Akt, IL-6 expression and STAT3 phosphorylation (n = 94; p <0.05). In conclusion, our data indicate that aberrant Akt signalling contributes to maintaining stemness in lung cancer TICs through a NF-kB/IL-6/ STAT3 pathway and provide novel potential therapeutic targets for eliminating these malignant cells in NSCLC.

AB - Here we report that the PI3K/Akt1/IL-6/STAT3 signalling pathway regulates generation and stem cell-like properties of Non-Small Cell Lung Cancer (NSCLC) tumor initiating cells (TICs). Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and tumorigenic potential of human immortalized bronchial cells (BEAS-2B) whereas Akt inhibition suppresses these activities in established (NCI-H460) and primary NSCLC cells. Matched microarray analysis of Akt1-interfered cells and LCSs identified IL-6 as a critical target of Akt signalling in NSCLC TICs. Accordingly, suppression of Akt in NSCLC cells decreases IL-6 levels, phosphorylation of IkK and IkB, NF-kB transcriptional activity, phosphorylation and transcriptional activity of STAT3 whereas active Akt1 up-regulates them. Exposure of LCSs isolated from NSCLC cells to blocking anti-IL-6 mAbs, shRNA to IL-6 receptor or to STAT3 markedly reduces the capability to generate LCSs, to self-renew and to form tumors, whereas administration of IL-6 to Akt-interfered cells restores the capability to generate LCSs. Finally, immunohistochemical studies in NSCLC patients demonstrated a positive correlative trend between activated Akt, IL-6 expression and STAT3 phosphorylation (n = 94; p <0.05). In conclusion, our data indicate that aberrant Akt signalling contributes to maintaining stemness in lung cancer TICs through a NF-kB/IL-6/ STAT3 pathway and provide novel potential therapeutic targets for eliminating these malignant cells in NSCLC.

KW - Akt1

KW - IL-6

KW - NSCLC

KW - STAT3

KW - Tumor initiating cells

UR - http://www.scopus.com/inward/record.url?scp=84952326791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952326791&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5626

DO - 10.18632/oncotarget.5626

M3 - Article

VL - 6

SP - 42667

EP - 42686

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -